Vimta Labs Ltd
Vimta Labs Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Vimta Labs Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3 FY25 Revenue from Operations: ₹899 Mn - Q3 FY24 Revenue from Operations: ₹746 Mn - Year-on-Year (YoY) Revenue Growth: 21.1% (from Q3 FY24 to Q3 FY25) - Total Income Q3 FY25: ₹911 Mn (including other income) - EBITDA Q3 FY25: ₹343 Mn with a margin of 37.6% (39.4% YoY growth) - PAT Q3 FY25: ₹175 Mn with a margin of 19.2% (43.0% YoY growth) - 9M FY25 Total Income: ₹2,521 Mn; 15.0% YoY growth compared to 9M FY24 - The presentation explicitly states an aspiration to reach revenues > ₹500 crore by FY 2025/26. Q3 FY25 EBITDA: ₹343 Mn, a 39.4% year-on-year (YoY) increase - Q3 FY25 Operating (EBITDA) Margin: 37.6%, improved from 32.7% YoY - Q3 FY25 Profit After Tax (PAT): ₹175 Mn, a 43.0% YoY increase -
From Vimta Labs Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY25 Revenue from Operations: ₹899 Mn
- Q3 FY24 Revenue from Operations: ₹746 Mn
- Year-on-Year (YoY) Revenue Growth: 21.1% (from Q3 FY24 to Q3 FY25)
- Total Income Q3 FY25: ₹911 Mn (including other income)
- EBITDA Q3 FY25: ₹343 Mn with a margin of 37.6% (39.4% YoY growth)
- PAT Q3 FY25: ₹175 Mn with a margin of 19.2% (43.0% YoY growth)
- 9M FY25 Total Income: ₹2,521 Mn; 15.0% YoY growth compared to 9M FY24
2 more points management made on revenue & sales performance
Profitability & Margins
See what Vimta Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Q3 FY25 Capex: Rs 657 Mn (Page 6)
- 9M FY25 Capex: Rs 958 Mn (Page 7)
- Core business strategies include capacity expansions (Page 30) but no specific plant or project details, amounts, or timelines are provided in the presentation.
- Infrastructure growth over years shows increase in facility size from 500 ft² in 1984 to 600,000+ ft² in 2024 (Page 15), indicating ongoing expansions.
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Vimta Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Vimta Labs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹109 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Vimta Labs Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY23 earnings call →
Others in Healthcare Services this season
- 3B Blackbio DX Ltd (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Child. (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Dr Lal Pathlabs Ltd (Q3 FY25)
Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…
- Thyrocare Technologies Ltd (Q3 FY25)
Franchise revenue grew 24% YoY, partnerships business grew 23% YoY, and radiology business increased 13% YoY. Key concall takeaways from Thyrocare Technologies…
Frequently Asked Questions
What were Vimta Labs Ltd Q3 FY25 results?
Q3 FY25 Revenue from Operations: ₹899 Mn - Q3 FY24 Revenue from Operations: ₹746 Mn - Year-on-Year (YoY) Revenue Growth: 21.1% (from Q3 FY24 to Q3 FY25) - Total Income Q3 FY25: ₹911 Mn (including other income) - EBITDA Q3 FY25: ₹343 Mn with a margin of 37.6% (39.4% YoY growth) - PAT Q3 FY25: ₹175 Mn with a margin of 19.2% (43.0% YoY growth) - 9M FY25 Total Income: ₹2,521 Mn; 15.0% YoY growth compared to 9M FY24 - The presentation explicitly states an aspiration to reach revenues > ₹500 crore by FY 2025/26. Q3 FY25 EBITDA: ₹343 Mn, a 39.4% year-on-year (YoY) increase - Q3 FY25 Operating (EBITDA) Margin: 37.6%, improved from 32.7% YoY - Q3 FY25 Profit After Tax (PAT): ₹175 Mn, a 43.0% YoY increase -
What is Vimta Labs Ltd share price analysis?
Vimta Labs Ltd currently shows a neutral. The stock trades at a P/E of 33.4 with a market cap of ₹2,696 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vimta Labs Ltd planning capital expenditure?
Q3 FY25 Capex: Rs 657 Mn (Page 6) - 9M FY25 Capex: Rs 958 Mn (Page 7) - Core business strategies include capacity expansions (Page 30) but no specific plant or project details, amounts, or timelines are provided in the presentation.
Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.